Aptorum Group Provides Update on DiamiR Biosciences Merger

Aptorum Group’s merger with DiamiR Biosciences is expected to close around July 20, 2026, with the post-merger company redomiciling to Delaware as Niki BioSolutions, Inc. Aptorum also announced a 1-for-10 reverse stock split, reducing shares from ~6,346,823 class A and ~1,796,934 class B to ~634,682 and ~179,693 shares, respectively, to help maintain Nasdaq’s minimum bid price compliance. The company expects trading on Nasdaq under the new ticker “NIKI” on July 20, 2026.

Analysis

This is a capital-structure event, not a fundamental inflection. Reverse-split-driven Nasdaq compliance tends to support the stock only mechanically for a few sessions; beyond that, the market usually re-prices the name on dilution risk, cash burn, and whether the merged entity can access capital without destroying equity value. The immediate winner is the company’s ability to stay listed; the real loser is liquidity, because lower share count often means wider spreads, thinner borrow, and more violent post-close moves.

For competitors, the signal is negative for other subscale biotech/diagnostic roll-ups trying to raise money: if this company needs a split to keep the tape clean, investors will demand similar or worse terms from peers. Any commercialization upside from the diagnostics side will be judged against better-capitalized testing platforms with real distribution and reimbursement visibility, which means the market may favor names like NTRA or DGX on any sector sympathy rather than this ticker on its own merits.

The contrarian view is that a Delaware redomestication plus merger can marginally improve institutional eligibility and future financing flexibility, so the structure cleanup is not meaningless. But that only matters if the next 1-2 filings show a credible cash runway and no near-term equity raise. If management taps the market again within the next 1-3 months, the reverse split will likely have been a setup for another leg lower; if they can go 2+ quarters without financing, the bearish readthrough weakens materially.

Key Decisions for Investors

• Avoid initiating long exposure in APM/NIKI into the July 20 effective date; the expected upside is mostly optical, while downside from post-close dilution or spread widening is more durable over 1-3 months.
• If the stock gaps higher on the symbol change, fade the move with a short-only stance in the first 1-5 trading days after the split, but only if borrow is available and liquidity is adequate; treat this as a tactical trade, not a core short.
• Set a financing alert on the next 8-K/10-Q: if cash runway is disclosed at <2 quarters, expect another 20-40% de-rating; if runway is >12 months and no raise is announced, cover any bearish exposure.
• Do not use TGT as a readthrough; there is no direct consumer-retail linkage here. Focus instead on broader small-cap diagnostics/biotech sentiment and whether money rotates into better-capitalized names like NTRA or DGX on any sector bid.